Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

I5409

Sigma-Aldrich

IRAK-1/4 Inhibitor I

≥98% (HPLC), solid

Sinonimo/i:

1-(2-(4-Morpholinyl)ethyl)-2-(3-nitrobenzoylamino)benzimidazole, N-(2-Morpholinylethyl)-2-(3-nitrobenzoylamido)-benzimidazole

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Formula empirica (notazione di Hill):
C20H21N5O4
Numero CAS:
Peso molecolare:
395.41
Numero MDL:
Codice UNSPSC:
51111800
ID PubChem:
NACRES:
NA.77

Livello qualitativo

Saggio

≥98% (HPLC)

Stato

solid

Colore

off-white to light yellow

Solubilità

DMSO: ≥5 mg/mL

Temperatura di conservazione

2-8°C

Stringa SMILE

O=C(C1=CC([N+]([O-])=O)=CC=C1)NC2=NC3=C(N2CCN4CCOCC4)C=CC=C3

InChI

1S/C20H21N5O4/c26-19(15-4-3-5-16(14-15)25(27)28)22-20-21-17-6-1-2-7-18(17)24(20)9-8-23-10-12-29-13-11-23/h1-7,14H,8-13H2,(H,21,22,26)
QTCFYQHZJIIHBS-UHFFFAOYSA-N

Applicazioni

IRAK-1/4 inhibitor I has been used in various studies to inhibit IRAK1 in hepatoma cell lines and head and neck squamous cell carcinoma (HNSCC) cell lines.

Azioni biochim/fisiol

IRAK-1/4 Inhibitor I is a novel benzimidazole that is a potent inhibitor of interleukin-1 receptor-associated kinases 1/4 (IRAK 1/4). IC50 values were 300 nM and 200 nM for IRAK-1 and -4, respectively, and >10,000 nM for a panel of 27 other kinases tested.
IRAK1 overexpression leads to the development of head and neck squamous cell carcinoma (HNSCC). Therefore, IRAK-1/4 inhibitor I might be a potential therapeutic for HNSCC tumors. Various experimental studies states that IRAK-1/4 inhibitor might have a potential to exhibit inhibitory effects on the nuclear factor (NF)-κB signaling pathway.

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Dispositivi di protezione individuale

Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges


Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 1

1 of 1

Targeting interleukin-1 receptor-associated kinase 1 for human hepatocellular carcinoma
Li N, et al.
Journal of Experimental & Clinical Cancer Research, 35(1), 140-140 (2016)
Federica Agliano et al.
Scientific reports, 10(1), 12100-12100 (2020-07-23)
Sterile stimuli can trigger inflammatory responses, and in some cases can lead to a variety of acute or chronic diseases. In this study, we hypothesize that a benzimidazole inhibitor may be used as a therapeutic in the treatment of sterile inflammation.
IRAK1 is a novel DEK transcriptional target and is essential for head and neck cancer cell survival
Adams AK, et al.
Oncotarget, 6(41), 43395-43395 (2015)
Jay P Powers et al.
Bioorganic & medicinal chemistry letters, 16(11), 2842-2845 (2006-03-28)
High-throughput screening of a small-molecule compound library resulted in the identification of a novel series of N-acyl 2-aminobenzimidazoles that are potent inhibitors of interleukin-1 receptor-associated kinase-4.
Kristin P Leister et al.
Current chemical genomics, 5, 21-29 (2011-06-07)
Tumor Necrosis Factor-α (TNF-α), a secreted cytokine, plays an important role in inflammatory diseases and immune disorders, and is a potential target for drug development. The traditional assays for detecting TNF-α, enzyme linked immunosorbent assay (ELISA) and radioimmunoassay, are not

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.